Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results